The Clinical Results of Benign Bone Tumor Treatment with Allograft or Autograft

Curettage and bone grafting is a method which can eliminate benign bone tumors while restoring structural integrity, reducing the risk of pathological fractures. The aim of this research is to study the clinical outcomes of using allografts and autografts, in treating benign bone neoplasms. A Historical Cohort was conducted on 119 patients with benign bone tumors treated with curettage and grafting from 2005 to 2011 in Shafa Yahyaiyan Hospital. The variables were age, gender, tumor type and location, staging, graft type, bone incorporation and recurrence. Data was analyzed with SPSS software, using descriptive statistics, tables, Fisher exact and LogRank tests. The significance level was chosen to be less than 0.05. The study was approved in Iran University of Medical Sciences. One hundred and nineteen patients, consisting of 63 treated with an allograft and 56 treated with an autograft were studied with a mean follow up of 37.5 months. 96.6% of the patients had complete incorporation of the graft into host bone after 6 months of surgery. There was no significant relationship between graft type and bone incorporation (P = 0.121). The estimated median time of recurrence was 20 months (SE= 6.55) in the allograft group and 9 months (SE= 0.77) in the autograft group using survival analysis. Using LogRank test, there was no significant difference between the median in the two methods (P = 0.288). Autografts and allografts seem to yield similar success rates in the treatment of benign bone tumors. Although more detailed researches with higher sample sizes are recommended for future studies.